Overview

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Mitogens